24/7 Market News Snapshot 24 October, 2025 – Theriva Biologics, Inc. (NYSE:TOVX)
DENVER, Colo., 24 October, 2025 (www.247marketnews.com) – (NYSE:TOVX) are discussed in this article.
Theriva Biologics, Inc. (NYSE American: TOVX), a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for cancer and related diseases, is experiencing significant market activity. Today, shares opened at $0.435 and have surged to $0.485, representing an impressive gain of over 41.8%. This follows a closing price of $0.342 in the previous trading session, reflecting a growing investor interest in the Company’s innovative approaches. With a current trading volume of 482.09 million shares, the heightened activity underscores a potential bullish sentiment among investors.
In light of this surge, Theriva Biologics has acknowledged unusual trading activity in its common stock, as reported on October 24, 2025. The Company asserts that there are no undisclosed material developments affecting its operations or known factors that could explain this atypical pattern. This clarification aligns with the Company’s commitment to transparency and investor communication, as it adheres to the regulations set forth in Section 401(d) of the NYSE Company Guide.
Theriva recently showcased expanded data from its pivotal VIRAGE trial concerning its flagship oncolytic adenovirus candidate, VCN-01, during a presentation at the European Society for Medical Oncology (ESMO) Annual Congress on October 13, 2025. VCN-01 is engineered to selectively replicate within tumor cells, potentially enhancing the effectiveness of standard cancer therapies by counteracting tumor-associated barriers. Furthermore, the Company is advancing additional innovative products, including SYN-004 (ribaxamase) for microbiome preservation during antibiotic courses and SYN-020, an intestinal alkaline phosphatase formulation targeting gastrointestinal and systemic disorders.
As Theriva Biologics dedicates its resources to revolutionizing cancer treatment, stakeholders can anticipate further updates as the Company progresses in its mission to improve patient outcomes.